Vasa Therapeutics Set to Present Groundbreaking Findings on VS-041 at ECM2026 Conference
Vasa Therapeutics, a pioneering biotechnology firm focused on innovative therapies for cardiovascular and metabolic aging, is poised to present significant findings on its investigational drug VS-041 during the upcoming ECM2026, the Extracellular Matrix Pharmacology Conference taking place from June 14-17, 2026, in Copenhagen, Denmark.
Dr. Noreen R. Henig, the Chief Medical Officer at Vasa, will deliver two key presentations: the first addressing preclinical efficacy and the safety and tolerability profile of VS-041, and the second detailing the design and rationale of an ongoing Phase 1c proof-of-mechanism trial. These presentations aim to showcase the promising potential of VS-041 in tackling heart failure with preserved ejection fraction (HFpEF) and its underlying pathologies.
Presentation Overview
- Presenter: Dr. Noreen R. Henig, MD
- Date and Time: June 16, 2026, from 14:00 to 15:00 CEST
- Presenter: Dr. Noreen R. Henig, MD
- Session: Poster Session A
- Date and Time: June 14, 2026, from 17:30 to 19:00 CEST
Dr. Henig conveyed that ECM2026 offers an exceptional platform to share Vasa's VS-041 program, especially given the conference’s focus on cutting-edge research in extracellular matrix biology. "We are excited to present our findings from both preclinical stages and the first-in-human studies, and to explain how our ongoing Phase 1c trial will explore VS-041's capacity to address the harmful ECM remodeling that characterizes HFpEF," she stated.
About ECM2026
The ECM2026 conference is a collaborative event that gathers leading researchers, clinicians, and industry experts to discuss advancements in our understanding of the extracellular matrix in various diseases. Its theme—"Fresh Ideas, Bright Science, Next-Generation Therapies"—captures the essence of how basic science is evolving into innovative therapeutic solutions. This year's conference aims to elevate the focus on fibrogenesis, which is linked to around 40% of fatalities in Western countries, and is a critical area in need of therapeutic breakthroughs.
Insights on VS-041
VS-041 is an oral small molecule being advanced by Vasa for potential use in treating HFpEF and associated fibroinflammatory disorders such as chronic kidney disease. Research indicates that this compound significantly minimized cardiac fibrosis and improved diastolic heart function in preclinical HFpEF models. Notably, VS-041 inhibits endotrophin release from cardiac fibroblasts, representing a novel target in therapy. In GLP toxicology trials, the safety and tolerability assessments underscored results that were encouraging, portraying an excellent safety profile that transitioned effectively into human trials. VS-041's recognition with Fast Track designation from the U.S. Food and Drug Administration (FDA) reflects its promise in meeting significant medical needs.
Vasa Therapeutics, headquartered in Encinitas, California, remains committed to delivering innovative solutions to critical unmet medical needs across cardiovascular, neuromuscular, and age-related disorders. By focusing on clinically relevant mechanisms and pioneering novel therapies, Vasa Therapeutics aspires to make meaningful impacts on patient outcomes. With a diverse pipeline targeting various conditions, including heart failure and related disorders, Vasa Therapeutics continues to strive for excellence in biopharmaceutical innovation.
Dr. Noreen R. Henig, the Chief Medical Officer at Vasa, will deliver two key presentations: the first addressing preclinical efficacy and the safety and tolerability profile of VS-041, and the second detailing the design and rationale of an ongoing Phase 1c proof-of-mechanism trial. These presentations aim to showcase the promising potential of VS-041 in tackling heart failure with preserved ejection fraction (HFpEF) and its underlying pathologies.
Presentation Overview
- - Oral Presentation:
- Presenter: Dr. Noreen R. Henig, MD
- Date and Time: June 16, 2026, from 14:00 to 15:00 CEST
- - Poster Presentation:
- Presenter: Dr. Noreen R. Henig, MD
- Session: Poster Session A
- Date and Time: June 14, 2026, from 17:30 to 19:00 CEST
Dr. Henig conveyed that ECM2026 offers an exceptional platform to share Vasa's VS-041 program, especially given the conference’s focus on cutting-edge research in extracellular matrix biology. "We are excited to present our findings from both preclinical stages and the first-in-human studies, and to explain how our ongoing Phase 1c trial will explore VS-041's capacity to address the harmful ECM remodeling that characterizes HFpEF," she stated.
About ECM2026
The ECM2026 conference is a collaborative event that gathers leading researchers, clinicians, and industry experts to discuss advancements in our understanding of the extracellular matrix in various diseases. Its theme—"Fresh Ideas, Bright Science, Next-Generation Therapies"—captures the essence of how basic science is evolving into innovative therapeutic solutions. This year's conference aims to elevate the focus on fibrogenesis, which is linked to around 40% of fatalities in Western countries, and is a critical area in need of therapeutic breakthroughs.
Insights on VS-041
VS-041 is an oral small molecule being advanced by Vasa for potential use in treating HFpEF and associated fibroinflammatory disorders such as chronic kidney disease. Research indicates that this compound significantly minimized cardiac fibrosis and improved diastolic heart function in preclinical HFpEF models. Notably, VS-041 inhibits endotrophin release from cardiac fibroblasts, representing a novel target in therapy. In GLP toxicology trials, the safety and tolerability assessments underscored results that were encouraging, portraying an excellent safety profile that transitioned effectively into human trials. VS-041's recognition with Fast Track designation from the U.S. Food and Drug Administration (FDA) reflects its promise in meeting significant medical needs.
Vasa Therapeutics, headquartered in Encinitas, California, remains committed to delivering innovative solutions to critical unmet medical needs across cardiovascular, neuromuscular, and age-related disorders. By focusing on clinically relevant mechanisms and pioneering novel therapies, Vasa Therapeutics aspires to make meaningful impacts on patient outcomes. With a diverse pipeline targeting various conditions, including heart failure and related disorders, Vasa Therapeutics continues to strive for excellence in biopharmaceutical innovation.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.